LNA-mediated microRNA silencing in non-human primates
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
microRNAs (miRNAs) are small regulatory RNAs that are important in development and disease and therefore represent a potential new class of targets for therapeutic intervention. Despite recent progress in silencing of miRNAs in rodents, the development of effective and safe approaches for sequence-specific antagonism of miRNAs in vivo remains a significant scientific and therapeutic challenge. Moreover, there are no reports of miRNA antagonism in primates. Here we show that the simple systemic delivery of a unconjugated, PBS-formulated locked-nucleic-acid-modified oligonucleotide (LNA-antimiR) effectively antagonizes the liver-expressed miR-122 in non-human primates. Acute administration by intravenous injections of 3 or 10 mg kg(-1) LNA-antimiR to African green monkeys resulted in uptake of the LNA-antimiR in the cytoplasm of primate hepatocytes and formation of stable heteroduplexes between the LNA-antimiR and miR-122. This was accompanied by depletion of mature miR-122 and dose-dependent lowering of plasma cholesterol. Efficient silencing of miR-122 was achieved in primates by three doses of 10 mg kg(-1) LNA-antimiR, leading to a long-lasting and reversible decrease in total plasma cholesterol without any evidence for LNA-associated toxicities or histopathological changes in the study animals. Our findings demonstrate the utility of systemically administered LNA-antimiRs in exploring miRNA function in rodents and primates, and support the potential of these compounds as a…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Recently, some reports have shown that an anti-microRNA antisense oligonucleotide efficiently blocked the function of the microRNA, thereby alleviating diseases in rodents and nonhuman primates (29,30).”
From ZFP36L1 and ZFP36L2 control LDLR mRNA stability via the ERK–RSK pathway (2014) · cites this paper as [29]
Citations
Cites
Bartel (2004) · doi:10.1016/s0092-8674(04)00045-5 · Cited by 34,714
Bioconductor: open software development for computational biology and bioinformatics
Gentleman, R. C., Carey, V. J., Bates, D. M., Bolstad, B., Dettling, M., Dudoit, S., Ellis, B., Gautier, L., Ge, Y., Gentry, J., et al. (2004) · Genome Biology · doi:10.1186/gb-2004-5-10-r80 · Cited by 12,172
Lewis, B. P., Burge, C. B., & Bartel, D. P. (2005) · Cell · doi:10.1016/j.cell.2004.12.035 · Cited by 11,855
The functions of animal microRNAs
Ambros, V. (2004) · Nature · doi:10.1038/nature02871 · Cited by 10,728
MicroRNA expression profiles classify human cancers
Lu, J., Getz, G., Miska, E. A., Alvarez-Saavedra, E., Lamb, J., Peck, D., Sweet-Cordero, A., Ebert, B. L., Mak, R. H., Ferrando, A. A., et al. (2005) · Nature · doi:10.1038/nature03702 · Cited by 9,539
MicroRNA signatures in human cancers
Calin, G. A., & Croce, C. M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1997 · Cited by 7,590
Oncomirs—MicroRNAs with a role in cancer
Esquela-Kerscher, A., & Slack, F. J. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1840 · Cited by 5,884
Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs
Lim, L. P., Lau, N. C., Garrett-Engele, P., Grimson, A., Schelter, J. M., Castle, J., Bartel, D. P., Linsley, P. S., & Johnson, J. M. (2005) · Nature · doi:10.1038/nature03315 · Cited by 4,755
Silencing of microRNAs in vivo with ‘antagomirs’
Krützfeldt, J., Rajewsky, N., Braich, R., Rajeev, K. G., Tuschl, T., Manoharan, M., & Stoffel, M. (2005) · Nature · doi:10.1038/nature04303 · Cited by 3,949
MicroRNA Targeting Specificity in Mammals: Determinants beyond Seed Pairing
Grimson, A., Farh, K. K.-H., Johnston, W. K., Garrett-Engele, P., Lim, L. P., & Bartel, D. P. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.06.017 · Cited by 3,766
Cited by
Items 701–800 of 1,004
Paulin, R., Courboulin, A., Barrier, M., & Bonnet, S. (2011) · Journal of Molecular Medicine · doi:10.1007/s00109-011-0788-5 · Cited by 48
“Moreover, in order to increase RNA stability, some chemical modifications added to the oligonucleotides like chemical sugar modifications 2′OMe or locked nucleic acid have been shown to lead to a better efficiency in therapeutic administration [98, 99].”
BackgroundNygaard, S., Skanderup, A. J., Lindow, M., Eriksen, J., Balslev, E., Flyger, H., Tolstrup, N., Møller, S., Krogh, A., & Litman, T. (2009) · BMC Medical Genomics · doi:10.1186/1755-8794-2-35 · Cited by 54
“cancer [9,10] and their potential as therapeutics is being explored [11].”
Self-citationAmato, F., Tomaiuolo, R., Nici, F., Borbone, N., Elce, A., Catalanotti, B., D'Errico, S., Morgillo, C., Rosa, G. D., Mayol, L., et al. (2014) · BioMed Research International · doi:10.1155/2014/610718 · Cited by 48
“In addition, locked nucleic acids (LNAs) have shown interesting activity [20, 21] especially when used in combination with unmodified DNA monomers.”
BackgroundCanonical and Non-Canonical Barriers Facing AntimiR Cancer Therapeutics
Cheng, C., Saltzman, W. M., & Slack, F. J. (2013) · Current Medicinal Chemistry · doi:10.2174/0929867311320290004 · Cited by 51
“delivered naked PS-modified LNA-based antimiRs to inhibit miR-122 enriched in the liver, which resulted in depletion of miR-122 in hepatocytes and the expected phenotype of lowered plasma cholesterol levels [41].”
BackgroundThe Effect of Intra-articular Injection of MicroRNA-210 on Ligament Healing in a Rat Model
Shoji, T., Nakasa, T., Yamasaki, K., Kodama, A., Miyaki, S., Niimoto, T., Okuhara, A., Kamei, N., Adachi, N., & Ochi, M. (2012) · The American Journal of Sports Medicine · doi:10.1177/0363546512458894 · Cited by 53
“The results of several therapeutic trials examining the regulation of endogenous miRNAs that are related to disease pathogenesis through in vivo administration of specific antisense oligoribonucleotides or double-stranded (ds) miRNAs have been reported.(10,33,48) Recently, several groups have reported that miRNA (miR)…”
BackgroundMicroRNAs-control of essential genes: Implications for pulmonary vascular disease
Joshi, S., McLendon, J., Comer, B. S., & Gerthoffer, W. (2011) · Pulmonary Circulation · doi:10.4103/2045-8932.87301 · Cited by 48
“A locked nucleic acid modified miR-122 when administered IV to green monkeys inhibits cholesterol synthesis.[54] Recently RNAi therapies targeting smooth muscle remodeling have also been shown to effective in animal models.”
MethodChen, Y., Gelfond, J., McManus, L. M., & Shireman, P. K. (2011) · Physiological Genomics · doi:10.1152/physiolgenomics.00136.2010 · Cited by 48
“Relative to the latter, the in vivo inhibition of specific miRNAs resulted in decreased plasma cholesterol in hypercholesterolemic mice and monkeys (17).”
BackgroundThe crystal structure of an ‘All Locked’ nucleic acid duplex
Eichert, A., Behling, K., Betzel, C., Erdmann, V., Fürste, J., & Förster, C. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq505 · Cited by 48
“For example, locked nucleic acid (LNA) building blocks are employed to improve targeting, specificity and stability of aptamers (4,5), utilized in DNAzymes to increase targeting and cleavage efficiency (6,7), used in miRNA silencing in direct antagonist (8) and LNAzyme approaches (9), functionalized as molecular beaco…”
MethodCoppola, V., Maria, R. D., & Bonci, D. (2009) · Endocrine Related Cancer · doi:10.1677/erc-09-0172 · Cited by 173
“The first therapeutic application of antagomiRs has proven promising: in mice and non-human primates, the effective and non-toxic antisense-mediated blocking of liver-specific miR-122 resulted in reduced cholesterol synthesis and improved fatty acid metabolism (Elmen et al. 2008).”
BackgroundDownregulation of tumor suppressor MBP-1 by microRNA-363 in gastric carcinogenesis.
Hsu, K.-W., Wang, A.-M., Ping, Y.-H., Huang, K.-H., Huang, T.-T., Lee, H.-C., Lo, S., Chi, C., & Yeh, T.-S. (2014) · Carcinogenesis · doi:10.1093/carcin/bgt285 · Cited by 48
“Effectively, miRNA expression is antagonized by antagomirs in mice (42) and attenuated by an unconjugated lockednucleic-acid-modified oligonucleotide in the liver of non-human primates (43).”
BackgroundMicroRNA-targeted therapeutics for lung cancer treatment
Xue, J., Yang, J., Luo, M., Cho, W. C. S., & Liu, X. (2016) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2017.1263298 · Cited by 50
“LNA against miR-122, miravirsen (SPC3649), developed by Santaris Pharma A/S was the first anti-miRNA-targeted therapy to reach clinical trials for treatment of HCV infection [17,133].”
BackgroundBanini, B. A., & Sanyal, A. J. (2016) · Clinical Medicine Insights Therapeutics · doi:10.4137/cmt.s18885 · Cited by 59
Braza‐Boïls, A., Marí‐Alexandre, J., Molina, P., Arnau, M. Á., Barceló‐Molina, M., Domingo, D., Girbés, J., Giner, J., Martínez‐Dolz, L., & Zorio, E. (2016) · Liver International · doi:10.1111/liv.13097 · Cited by 53
“Conversely, other studies have reported that the transient inhibition of miR-122-5p in mice protects against dyslipidaemia (40, 41) and liver steatosis (17, 41).”
BackgroundDávalos, A., & Fernandez-Hernando, C. F. (2013) · Pharmacological Research · doi:10.1016/j.phrs.2013.02.005 · Cited by 56
miR-222 inhibits pathological cardiac hypertrophy and heart failure
Liu, X., Li, H., Hastings, M. H., Xiao, C., Damilano, F., Platt, C., Lerchenmüller, C., Zhu, H., Wei, X. P., Yeri, A., et al. (2023) · Cardiovascular Research · doi:10.1093/cvr/cvad184 · Cited by 49
“C ), LNA-anti-miR-222-treated animals showed dramatically accelerated functional decline after TAC ( Figure 2A ).”
InfluentialMolecular Targets and Signaling Pathways of microRNA-122 in Hepatocellular Carcinoma
Chun, K. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14071380 · Cited by 50
Role of Non-Coding RNAs in Stroke
Tiedt, S., & Dichgans, M. (2018) · Stroke · doi:10.1161/strokeaha.118.021010 · Cited by 53
Circulating miRNAs as biomarkers for early diagnosis of coronary artery disease
Zhang, L., Zhang, Y., Zhao, Y., Wang, Y., Ding, H., Xue, S., & Li, P. (2018) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2018.1503650 · Cited by 58
MicroRNA Theranostics in Prostate Cancer Precision Medicine
Matin, F., Jeet, V., Clements, J. A., Yousef, G. M., & Batra, J. (2016) · Clinical Chemistry · doi:10.1373/clinchem.2015.242800 · Cited by 62
Epigenetic mechanisms in non-alcoholic fatty liver disease: An emerging field
Gallego‐Durán, R., & Romero-Gómez, M. (2015) · World Journal of Hepatology · doi:10.4254/wjh.v7.i24.2497 · Cited by 52
Temporal and spatial regulation of microRNA activity with photo-activatable cantimirs
Zheng, G.-H., Cochella, L., Liu, J., Hobert, O., & Li, W.-H. (2011) · ACS Chemical Biology · doi:10.1021/cb200290e · Cited by 46
Christoffersen, C., Pedersen, T. X., Gordts, P. L. S. M., Roebroek, A., Dahlbäck, B., & Nielsen, L. B. (2010) · Circulation Research · doi:10.1161/circresaha.109.211086 · Cited by 52
Polymer nanocarriers for MicroRNA delivery
Kapadia, C. H., Luo, B., Dang, M. N., Irvin-Choy, N. S., Valcourt, D. M., & Day, E. S. (2019) · Journal of Applied Polymer Science · doi:10.1002/app.48651 · Cited by 62
HDL and microRNA therapeutics in cardiovascular disease
Michell, D. L., & Vickers, K. C. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.09.001 · Cited by 49
Sharifi, M., Salehi, R., Gheisari, Y., & Kazemi, M. (2014) · Molecular Biology Reports · doi:10.1007/s11033-014-3134-5 · Cited by 45
RetractedMicroarray Analysis of microRNA Expression during Axolotl Limb Regeneration
Holman, E. C., Campbell, L. J., Hines, J. F., & Crews, C. M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0041804 · Cited by 48
“For Northern Blots we followed published protocols [54,55] with modifications as follows: ten micrograms of total RNA per sample were dissolved in Gel Loading Buffer II (Ambion), heated at 95uC for 5 min, loaded onto denaturing 15% TBE-Urea denaturing, SequaGel Sequencing gel (National Diagnostics, Atlanta, GA) along…”
MethodTherapeutic modulation of miRNA for the treatment of proinflammatory lung diseases
Hassan, T. M., McKiernan, P. J., McElvaney, N. G., Cryan, S., & Greene, C. M. (2012) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.11.175 · Cited by 41
Potential Applications of MicroRNAs in Cancer Diagnosis, Prognosis, and Treatment
Sandhu, S. K., & Garzon, R. (2011) · Seminars in Oncology · doi:10.1053/j.seminoncol.2011.08.007 · Cited by 47
Emerging Role of MicroRNAs in Drug-Resistant Breast Cancer
Majumder, S., & Jacob, S. T. (2011) · Gene Expression · doi:10.3727/105221611x13176664479287 · Cited by 46
“Although this approach helps clinicians to make in- (26).”
BackgroundZhu, T., Corraze, G., Plagnes-Juan, E., Quillet, E., Dupont-Nivet, M., & Skiba-Cassy, S. (2018) · American Journal of Physiology. Regulatory Integrative and Comparative Physiology · doi:10.1152/ajpregu.00179.2017 · Cited by 45
“The inhibition of miR-122 resulted in reduced plasma cholesterol levels in mice and fish (25, 50).”
BackgroundTherapeutic Applications of Ribozymes and Riboswitches
Lange, M. J., & Burke, D. H. (2014) · Methods in Molecular Biology · doi:10.1007/978-1-62703-730-3 · Cited by 45
Baek, D., Lee, K.-M., Park, K. W., Suh, J. W., Choi, S. M., Park, K. H., Lee, J. W., & Kim, S. (2018) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2018.09.015 · Cited by 46
“Intra-articular injections of 50 mL of PBS, LNA-anti-miR-sc (100 nM), and LNA-anti-miR-449a (100 nM) were performed 8 weeks after DMM surgery twice a week and immediately following DMM surgery twice a week for 12 weeks.(55,61) At 8, 12, and 16 weeks post-DMM, the rats were sacrificed under anesthesia and knee joints w…”
BackgroundMethodBela-ong, D., Schyth, B. D., Zou, J., Secombes, C., & Lorenzen, N. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.04.092 · Cited by 44
Borkowski, R., Du, L., Zhao, Z., McMillan, E. A., Kosti, A., Yang, C.-R., Suraokar, M. B., Wistuba, I., Gazdar, A., Minna, J., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1329 · Cited by 44
“bioavailability, even without any packaging or carrier (14, 16, 17).”
BackgroundNon-coding RNAs in lung cancer
Ricciuti, B., Mecca, C., Crinò, L., Baglivo, S., Cenci, M., & Metro, G. (2014) · Oncoscience · doi:10.18632/oncoscience.98 · Cited by 43
“These kinds of molecules could play a considerable role in miRNA silencing processes, thus suppressing those miRNAs with oncogenic properties [230-231].”
BackgroundChristian, P., & Su, Q. (2014) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00194.2014 · Cited by 46
“Other miR-122-deficient animal models also displayed reduced plasma cholesterol levels (22, 35, 90).”
BackgroundHatakeyama, H., Murata, M., Sato, Y., Takahashi, M. M., Minakawa, N., Matsuda, A., & Harashima, H. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.10.023 · Cited by 83
“A widely employed approach in loss-of-function studies is to use chemically modified anti-miRs [3-5,12-14], and LNA-modified anti-miR has some potential for clinical use in the treatment of HCV infections [15].”
BackgroundInfluentialTherapeutic Opportunities for Targeting microRNAs in Cancer
Taylor, M. A., & Schiemann, W. P. (2014) · Journal of Green Engineering · doi:10.1186/2052-8426-2-30 · Cited by 49
“More recently, LNA chemistry served as the foundation during the synthesis of the anti-miR122 agent developed by Santaris Pharma (SPC3649), which is highly effective in downregulating miR-122 levels in the liver in non-human primates (African Green Monkeys; [117]), and in treating chronic HCV infection in chimpanzees…”
MethodMicroRNAs in Cardiometabolic Disease
Najafi-Shoushtari, S. H. (2011) · Current Atherosclerosis Reports · doi:10.1007/s11883-011-0179-y · Cited by 42
Therapeutic Advances in MicroRNA Targeting
Montgomery, R. L., & van Rooij, E. (2011) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e3181f603d0 · Cited by 44
“This was accompanied by depletion of mature miR-122 and dose-dependent lowering of plasma cholesterol.(24,25) By now, the LNA derivatives also have been shown to be efficacious in chronically infected chimpanzees by suppressing hepatitis C virus viremia and improvement of hepatitis C virus-induced liver pathology(26)…”
BackgroundMicroRNA schizophrenia: Etiology, biomarkers and therapeutic targets
Zhang, H.-C., Du, Y., Chen, L., Yuan, Z., & Cheng, Y. (2023) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2023.105064 · Cited by 50
Decreased MicroRNA-26a expression causes cisplatin resistance in human non-small cell lung cancer
Yang, Y., Zhang, P., Zhao, Y., Yang, J., Jiang, G., & Fan, J. (2015) · Cancer Biology & Therapy · doi:10.1080/15384047.2015.1095405 · Cited by 45
MicroRNAs as potential target in human bone and soft tissue sarcoma therapeutics
Varshney, J., & Subramanian, S. (2015) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2015.00031 · Cited by 40
Implications of microRNAs in the pathogenesis of diabetes
Park, S., Jeong, H.-J., Yang, W., & Lee, W. (2013) · Archives of Pharmacal Research · doi:10.1007/s12272-013-0017-6 · Cited by 43
“Since miR-122 is most abundantly expressed in the liver, the functional significance of miR-122 and its therapeutic potential have been studied by various methods (Elmen et al. 2008; Esau et al. 2006; Krutzfeldt et al. 2005).”
BackgroundMicroRNAs and lipoproteins: A connection beyond atherosclerosis?
Norata, G. D., Sala, F., Catapano, A. L., & Fernandez-Hernando, C. F. (2012) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2012.11.019 · Cited by 46
Chistiakov, D. A., Sobenin, I. A., & Orekhov, A. N. (2012) · Drug Delivery · doi:10.3109/10717544.2012.738436 · Cited by 46
MicroRNAs, Hepatitis C Virus, and HCV/HIV-1 Co-Infection: New Insights in Pathogenesis and Therapy
Gupta, A. A., Swaminathan, G., Martín‐García, J., & Navas, S. (2012) · Viruses · doi:10.3390/v4112485 · Cited by 48
“The cellular function of miR-122 was also confirmed in non-human primates using a locked- nucleic-acid modified oligonucleotides (LNA-antimiRs) platform to silence the endogenous miRNA [75].”
MicroRNAs in Hepatobiliary and Pancreatic Cancers
Saito, Y., Suzuki, H., Matsuura, M., Sato, A., Kasai, Y., Yamada, K., Saito, H., & Hibi, T. (2011) · Front. Gene. · doi:10.3389/fgene.2011.00066 · Cited by 43
“A recent study have shown that chemically engineered oligonucleotides, termed locked-nucleic-acid (LNA)-modified miRNAs, were found to be specific inhibitors of endogenous miRNAs in non-human primates (Elmen et al., 2008).”
Micro-RNA Expression and Function in Lymphomas
Sandhu, S. K., Croce, C. M., & Garzon, R. (2011) · Advances in Hematology · doi:10.1155/2011/347137 · Cited by 42
“An alternative to AMOs is locked nucleic acid- (LNA-) based anti-miRs, which have been shown to be more stable and less toxic in inhibiting endogenous miRNAs in vivo [77, 78].”
BackgroundMethodEpigenetic Architecture and miRNA: Reciprocal Regulators
Wiklund, E. D., Kjems, J., & Clark, S. J. (2010) · Epigenomics · doi:10.2217/epi.10.51 · Cited by 44
MicroRNAs in Cardiovascular Diseases: Biology and Potential Clinical Applications
Kartha, R. V., & Subramanian, S. (2010) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-010-9172-z · Cited by 49
Reschke, C. R., Silva, L. F. A., Vangoor, V. R., Rosso, M., David, B., Cavanagh, B. L., Connolly, N. M. C., Brennan, G. P., Sanz-Rodriguez, A., Mooney, C., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.02.021 · Cited by 42
“) with 10 or 30 mg/kg Ant-134, with dosing guided by previous studies.(17) Control mice were systemically injected with a scrambled LNA-modified ASO (Scr).”
BackgroundMethodmiR-197: A novel biomarker for cancers
Wang, D., Chen, X., Yu, D., Yang, S., Shen, H.-Y., Sha, H., Zhong, S., Zhao, J., & Tang, J. (2016) · Gene · doi:10.1016/j.gene.2016.06.035 · Cited by 47
“Joacim et.al had confirmed that locked-nucleic-acid-modified oligonucleotide (LNA-antimiR) could antagonized the efficacy of the overexpressed miRNAs (Elmen et al., 2008), which provided an effective way for the treatment of miR-197.”
BackgroundLi, H., Huang, Y., Ma, C., Yu, X., Zhang, Z., & Shen, L. (2014) · Clinical Journal of Pain · doi:10.1097/ajp.0000000000000070 · Cited by 43
Davis, C. J., Clinton, J. M., & Krueger, J. M. (2012) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00940.2012 · Cited by 45
“In vivo silencing of miRNAs using modified oligonucleotides has been demonstrated previously by others (11, 12, 20).”
MethodMicroRNAs: potential biomarker in organ transplantation.
Shan, J., Feng, L., Luo, L., Wu, W.-Q., Li, C., Li, S.-F., & Li, Y.-P. (2011) · Transplant Immunology · doi:10.1016/j.trim.2011.03.004 · Cited by 42
Silencing Viral MicroRNA as a Novel Antiviral Therapy?
Moens, U. (2009) · Journal of Biomedicine and Biotechnology · doi:10.1155/2009/419539 · Cited by 42
“LNA injections against miR-122, a cellular miRNA involved in lipid metabolism, resulted in efficient and long-lasting decrease in plasma cholesterol in African green monkeys without any evidence for toxicities [30].”
BackgroundBiological roles of microRNAs in the control of insulin secretion and action.
Calderari, S., Diawara, M., Garaud, A., & Gauguier, D. (2017) · Physiological Genomics · doi:10.1152/physiolgenomics.00079.2016 · Cited by 42
“These observations account for reduced HFD-induced nonalcoholic fatty liver disease (NAFLD) in mice inactivated for miR-122 (14, 15, 82).”
BackgroundMicroRNA-205 suppresses proliferation and promotes apoptosis in laryngeal squamous cell carcinoma
Tian, L., Zhang, J., Ge, J., Xiao, H., Lu, J., Fu, S., Liu, M., & Sun, Y. (2013) · Medical Oncology · doi:10.1007/s12032-013-0785-3 · Cited by 41
“Moreover, the possible therapeutic use of miRNAs has been studied by using antagomirs to silence miRNAs in mice [14] and non-human primates [15].”
BackgroundRoles of MicroRNAs in the Life Cycles of Mammalian Viruses
Gottwein, E. (2013) · Current topics in microbiology and immunology · doi:10.1007/978-3-642-37765-5_8 · Cited by 46
Epigenetics and vascular diseases
Stratton, M. S., Farina, F. M., & Elia, L. (2019) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2019.06.010 · Cited by 51
Demerdash, H. M., Hussien, H. M., Hassouna, E. M., & Arida, E. (2017) · BioMed Research International · doi:10.1155/2017/1806069 · Cited by 42
Lin, Y., Zeng, Y., Zhang, F., Xue, L., Huang, Z., Li, W., & Guo, M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0069230 · Cited by 40
miRNA Therapeutics: Delivery and Biological Activity of Peptide Nucleic Acids Targeting miRNAs
Fabbri, E., Brognara, E., Borgatti, M., Lampronti, I., Finotti, A., Bianchi, N., Sforza, S., Tedeschi, T., Manicardi, A., Marchelli, R., et al. (2011) · Epigenomics · doi:10.2217/epi.11.90 · Cited by 47
Involvement of microRNAs in lung cancer biology and therapy
Liu, X., Sempere, L. F., Guo, Y., Korc, M., Kauppinen, S., Freemantle, S. J., & Dmitrovsky, E. (2011) · Translational research · doi:10.1016/j.trsl.2011.01.001 · Cited by 37
Self-citationSylArray: a web server for automated detection of miRNA effects from expression data
Bartonicek, N., & Enright, A. (2010) · Bioinform. · doi:10.1093/bioinformatics/btq545 · Cited by 41
microRNA-92a promotes CNS autoimmunity by modulating the regulatory and inflammatory T cell balance
Fujiwara, M., Raheja, R., Garo, L. P., Ajay, A. K., Kadowaki-Saga, R., Karandikar, S. H., Gabriely, G., Krishnan, R., Beynon, V., Paul, A., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci155693 · Cited by 50
“We and others have previously leveraged miRNA-based therapeutics in inflammation and CNS autoimmunity (27, 28, 55, 56).”
BackgroundHu, X., Dasgupta, C., Xiao, D., Huang, X., Yang, S., & Zhang, L. (2017) · Hypertension · doi:10.1161/hypertensionaha.117.09864 · Cited by 49
Repression of Esophageal Neoplasia and Inflammatory Signaling by Anti-miR-31 Delivery In Vivo.
Taccioli, C., Garofalo, M., Chen, H.-P., Jiang, Y.-B., Tagliazucchi, G., di Leva, G., Alder, H., Fadda, P., Middleton, J. D., Smalley, K., et al. (2015) · Journal of the National Cancer Institute · doi:10.1093/jnci/djv220 · Cited by 40
Baselga-Escudero, L., Bladé, C., Ribas-Latre, A., Casanova, E., Salvadó, M., Arola, L., & Arola-Arnal, A. (2014) · Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2013.09.014 · Cited by 40
“miR-122 expression is liver specific and plays a critical role in maintaining liver homeostasis [13,14]; its inhibition has been associated with the dysregulation of genes involved in liver lipid metabolism, such as fatty acid synthase (Fas), as well as genes that regulate fatty acid β-oxidation [13,15–18].”
BackgroundRegulation of the expression of the liver cancer susceptibility gene MICA by microRNAs
Kishikawa, T., Otsuka, M., Yoshikawa, T., Ohno, M., Takata, A., Shibata, C., Kondo, Y., Akanuma, M., Yoshida, H., & Koike, K. (2013) · Scientific Reports · doi:10.1038/srep02739 · Cited by 40
Li, H., Shen, L., Ma, C., & Huang, Y.-G. (2013) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2013.1381 · Cited by 40
“The realization that the inappropriate production of individual miRNAs in a specific region of the pain transmission pathway contributes to neuropathic pain has reinvigorated antisense oligonucleotide (ASO) drug development (44,45).”
Seth, P. P., Jazayeri, A., Yu, J., Allerson, C. R., Bhat, B., & Swayze, E. E. (2012) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2012.34 · Cited by 44
Role of microRNAs in cardiac hypertrophy, myocardial fibrosis and heart failure
Dong, D., & Yang, B. (2011) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2011.04.010 · Cited by 41
MicroRNA: Potential Targets for the Development of Novel Drugs?
Wu, W. (2010) · Drugs in R&D · doi:10.1007/bf03259769 · Cited by 39
“No acute or sub-acute toxicity was observed in mice and non-human primates treated with locked nucleotide acid (LNA) anti-miRs.([58,59]) Due to the advancement of the delivery technology and the relative safety of miRNAs-based treatment in the preclinical trial,([4]) a clinical trial of LNA-antimiR -122 (SPC3649) in h…”
BackgroundMicroRNAs and Beyond: The Heart Reveals Its Treasures
Schroen, B. L. M., & Heymans, S. R. B. (2009) · Hypertension · doi:10.1161/hypertensionaha.109.133942 · Cited by 42
Prospects for Therapeutic Targeting of MicroRNAs in Human Immunological Diseases
Luck, M. E., Muljo, S. A., & Collins, C. B. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1403146 · Cited by 43
Plowright, A. T., Engkvist, O., Gill, A. L., Knerr, L., & Wang, Q. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201307034 · Cited by 43
Vislovukh, A. A., Vargas, T. R., Polesskaya, A., & Groisman, I. (2014) · World Journal of Biological Chemistry · doi:10.4331/wjbc.v5.i1.40 · Cited by 39
Shibata, C., Otsuka, M., Kishikawa, T., Yoshikawa, T., Ohno, M., Takata, A., & Koike, K. (2013) · Molecular and Cellular Therapies · doi:10.1186/2052-8426-1-5 · Cited by 39
“In these three cases, no LNA-associated toxicity or histopathological changes were found in mice and nonhuman primates after short-term administration of the oligonucleotides [31,33,34].”
BackgroundAstakhova, I. K., & Wengel, J. (2013) · Chemistry · doi:10.1002/chem.201202621 · Cited by 39
MicroRNA, SND1, and alterations in translational regulation in colon carcinogenesis.
Tsuchiya, N., & Nakagama, H. (2010) · Mutation research · doi:10.1016/j.mrfmmm.2010.09.001 · Cited by 39
Glioma angiogenesis: Towards novel RNA therapeutics
Würdinger, T., & Tannous, B. A. (2009) · Cell Adhesion & Migration · doi:10.4161/cam.3.2.7910 · Cited by 57
Wang, Y., Yuan, Y., Gao, Y., Li, X., Tian, F., Liu, F., Du, R., Li, P., Wang, F., Xu, S., et al. (2019) · Brain and Development · doi:10.1016/j.braindev.2019.04.010 · Cited by 48
Highly efficient silencing of microRNA by heteroduplex oligonucleotides
Yoshioka, K., Kunieda, T., Asami, Y., Guo, H., Miyata, H., Yoshida‐Tanaka, K., Sujino, Y., Piao, W., Kuwahara, H., Nishina, K., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz492 · Cited by 44
“In these experiments, we used an HDO-antimiR with two LNA-nucleotide mismatches of the miR-122 sequence as a negative control (18), and observed no binding of miRNA.”
BackgroundMethodInfluentialRegulatory RNAs and Cardiovascular Disease – With a Special Focus on Circulating MicroRNAs
Dlouhá, D., & Hubacek, J. A. (2017) · Physiological Research · doi:10.33549/physiolres.933588 · Cited by 42
“Inhibition of miR-122 levels in the liver results in a significant reduction of plasma cholesterol levels in mice and non-human primates (Elmen et al. 2008).”
miRNA and cholesterol homeostasis
Jeon, T.-I., & Osborne, T. F. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2016.01.005 · Cited by 47
“Follow-up studies also showed that reduced miR-122 reduced circulating cholesterol levels in non-human primates [28].”
BackgroundMicroRNA Screening and the Quest for Biologically Relevant Targets
Eulálio, A., & Mano, M. (2015) · SLAS DISCOVERY · doi:10.1177/1087057115578837 · Cited by 37
MicroRNAs Implicated in the Immunopathogenesis of Lupus Nephritis
Chafin, C. B., & Reilly, C. M. (2013) · Clinical and Developmental Immunology · doi:10.1155/2013/430239 · Cited by 40
Applications of mass spectrometry to the study of siRNA
Beverly, M. B. (2010) · Mass Spectrometry Reviews · doi:10.1002/mas.20260 · Cited by 43
“The LNA modification which joins the 20 and 40 position of the ribose via a 20 O–40 methylene linkage has also been reported to improve siRNA stability while retaining activity (Elmen et al., 2005, 2008; Mook et al., 2007).”
Backgroundrna Interference and micro-rna–Oriented Therapy in Cancer: Rationales, Promises, and Challenges
Duchaîne, T. F., & Slack, F. J. (2009) · Current Oncology · doi:10.3747/co.v16i4.486 · Cited by 39
Weigert, A., Mora, J., Sekar, D., Syed, S. N., & Brüne, B. (2016) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-39406-0_9 · Cited by 51
Wang, G., Ma, X., Huang, W., Wang, S., Lou, A., Wang, J., Tu, Y., Cui, W., Zhou, W., Zhang, W., et al. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02597-z · Cited by 42
“In addition, it is important to identify the long-term effects of miRNA mimics and inhibitors, since these compounds can persist in tissues for several months [36].”
BackgroundMicroRNA Cues from Nature: A Roadmap to Decipher and Combat Challenges in Human Health and Disease?
Singh, G., & Storey, K. B. (2021) · Cells · doi:10.3390/cells10123374 · Cited by 43
“Another study that has entered clinical trials involves an antisense RNA oligo called LNA miravirsen that has complementarity to the 5′ end of miR-122 and suppresses its action; it has been used for the treatment of the Hepatitis C virus and for the lowering of cholesterol in a nonhuman primate model [168,169].”
BackgroundRNA Interference and Nanotechnology: A Promising Alliance for Next Generation Cancer Therapeutics
Swaminathan, G., Nadukkandy, A. S., Kumar, A., Byroju, V. V., Durgempudi, V. R., & Kumar, L. D. (2021) · Frontiers in Nanotechnology · doi:10.3389/fnano.2021.694838 · Cited by 51
“Modification of these nucleic acid molecules so as to have extended cholesterol, glycan, and folate branches that bind to cell receptors and incorporating these within nanocarriers, liposomes, and aptamers to do cellspecific targeting have shown promising results when induced in mice and non-human primates (Elmén et a…”
BackgroundMicroRNAs as a Novel Tool in the Diagnosis of Liver Lipid Dysregulation and Fatty Liver Disease
Yu, J., Peng, J., Luan, Z., Zheng, F., & Su, W. (2019) · Molecules · doi:10.3390/molecules24020230 · Cited by 41
Cao, H., Yu, W., Li, X., Wang, J., Gao, S., Holton, N. E., Eliason, S. L., Sharp, T., & Amendt, B. A. (2016) · Gene Therapy · doi:10.1038/gt.2016.22 · Cited by 42
“This system and others can inhibit miR activity without degradation of the miR 24,29 .”
Wu, Q., Li, J. V., Seyfried, F., le Roux, C. W., Ashrafian, H., Athanasiou, T., Fenske, W. K., Darzi, A. W., Nicholson, J. K., Holmes, E. C., et al. (2015) · International Journal of Obesity · doi:10.1038/ijo.2015.33 · Cited by 40
Yao, H., & Li, J. (2014) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.219816 · Cited by 40
“There are three types of antisense oligonucleotides: locked nucleic acids, anti-miRNA oligonucleotides, and antagomirs developed for inhibiting miRNAs (Krutzfeldt et al., 2005; Elmen et al., 2008; Esau, 2008).”
BackgroundMicroRNA-dependent targeting of the extracellular matrix as a mechanism of regulating cell behavior
Ibrahim, S., Hassan, H., & Götte, M. (2014) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2014.01.022 · Cited by 38
Metadata
- Authors
- Elmén, J., Lindow, M., Schütz, S., Lawrence, M., Petri, A., Obad, S., Lindholm, M., Hedtjärn, M., Hansen, H. F., Berger, U., Gullans, S., Kearney, P., Sarnow, P., Straarup, E. M., & Kauppinen, S.
- Affiliations
- Stanford Medicine (US)
- University of Copenhagen (DK)
- Corresponding author
- Kauppinen, Sakari
- Venue
- Nature
- Published
- 2008-03-26
- Volume
- 452
- Issue
- 7189
- Pages
- 896-899
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2142310248
- Cited by
- 1,589
- References
- 0
- Citations by year
- 2026: 13 · 2025: 20 · 2024: 23 · 2023: 23 · 2022: 54 · 2021: 48 · 2020: 63 · 2019: 66 · 2018: 62 · 2017: 75 · 2016: 100 · 2015: 113 · 2014: 139 · 2013: 176 · 2012: 175
- FWCI
- 60.00
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- microRNA silencing, locked nucleic acid, miR-122, cholesterol lowering, vervet monkey, non-human primates, hepatocyte uptake, heteroduplex formation, serum cholesterol, siRNA, oligonucleotide toxicity, gene expression regulation, drug target validation
- MeSH terms
- Animals, Chlorocebus aethiops, Female, Mice, Inbred C57BL, Oligonucleotides, Gene Silencing, MicroRNAs, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.